https://surrozen.com/press_releases/surrozen-launches-into-regenerative-medicine-with-33-million-in-series-a-financing-led-by-the-column-group/ 2017-02-15T08:00:00+00:00 https://surrozen.com/press_releases/surrozen-strengthens-leadership-team-with-addition-of-new-ceo-and-scientific-co-founder/ 2018-04-04T08:00:00+00:00 https://surrozen.com/press_releases/surrozen-raises-50-million-in-series-b-financing-to-advance-regenerative-antibody-platforms-and-liver-disease-candidates/ 2019-03-14T14:00:00+00:00 https://surrozen.com/press_releases/surrozen-appoints-dr-trudy-vanhove-as-chief-medical-officer/ 2019-04-11T14:01:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-cowen-and-company-40th-annual-health-care-conference/ 2020-03-02T15:00:00+00:00 https://surrozen.com/press_releases/surrozen-announces-publication-of-antibody-platform-technology-in-cell-chemical-biology/ 2020-03-30T17:42:00+00:00 https://surrozen.com/press_releases/surrozen-scientific-founder-roel-nussephd-receives-prestigious-canada-gairdner-international-award-for-biomedical-research/ 2020-04-06T14:00:00+00:00 https://surrozen.com/press_releases/surrozen-announces-publication-of-two-abstracts-providing-evidence-for-liver-targeted-tissue-regeneration/ 2020-05-04T14:00:00+00:00 https://surrozen.com/press_releases/surrozen-raises-50-million-in-series-c-financing-to-advance-candidates-to-human-clinical-trials/ 2020-06-19T11:00:00+00:00 https://surrozen.com/press_releases/update-surrozen-raises-50-million-in-series-c-financing-to-advance-candidates-to-human-clinical-trials/ 2020-06-19T14:00:00+00:00 https://surrozen.com/press_releases/surrozen-announces-publication-of-second-antibody-platform-technology-in-scientific-reports/ 2020-08-19T14:00:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-morgan-stanley-18th-annual-global-healthcare-conference/ 2020-09-16T11:00:00+00:00 https://surrozen.com/press_releases/surrozen-expands-board-of-directors-with-appointment-of-david-j-woodhouseph-d/ 2020-09-25T11:00:00+00:00 https://surrozen.com/press_releases/surrozen-awarded-nih-grant-to-support-development-of-szn-043-a-liver-specific-regenerative-antibodyfor-the-treatment-of-severe-alcoholic-hepatitis/ 2020-10-15T11:00:00+00:00 https://surrozen.com/press_releases/surrozen-appoints-charles-williams-as-chief-financial-officer/ 2020-10-29T11:00:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-the-stifel-2020-virtual-healthcare-conference/ 2020-11-12T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-expands-board-of-directors-with-appointment-of-shao-lee-lin-m-d-ph-d/ 2021-02-02T23:31:00+00:00 https://surrozen.com/press_releases/surrozen-expands-board-of-directors-with-appointment-of-mary-haak-frendschoph-d/ 2021-03-11T19:37:00+00:00 https://surrozen.com/press_releases/surrozen-and-consonance-hfw-acquisition-corp-announce-business-combination-creating-publicly-listed-leader-in-wnt-biology-and-tissue-regeneration/ 2021-04-15T15:52:00+00:00 https://surrozen.com/press_releases/surrozen-strengthens-board-of-directors-with-appointments-of-mace-rothenberg-m-d-and-christopher-chai/ 2021-05-06T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-presents-data-from-lead-wnt-modulating-antibody-programs-szn-1326-and-szn-043in-six-oral-and-poster-presentations-at-2021-digestive-disease-week-conference/ 2021-05-24T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-publishes-article-in-nature-communications-demonstrating-selective-wnt-mimetics-stimulate-bone-mass-accrual-in-disease-models-of-osteoporosisaging-and-long-bone-fracture/ 2021-06-01T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-presents-data-supporting-potential-of-szn-043-at-the-liver-biology-conference-fundamental-mechanisms-and-translational-applications/ 2021-06-17T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-presents-data-at-2021-international-liver-conference-for-wnt-modulating-antibody-szn-043/ 2021-06-25T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-presents-new-data-demonstrating-superior-activity-of-szn-1326-in-preclinical-inflammatory-bowel-disease-models-at-16th-congress-of-the-european-crohns-and-colitis-organisation-ecco/ 2021-07-09T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-canaccord-genuitys-41st-annual-growth-conference/ 2021-08-05T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-debuts-as-publicly-traded-leader-in-wnt-biology-and-tissue-regeneration/ 2021-08-11T21:30:00+00:00 https://surrozen.com/press_releases/surrozen-announces-appointment-of-liz-nguyen-as-vice-president-and-head-of-human-resources/ 2021-09-23T12:30:00+00:00 https://surrozen.com/press_releases/surrozen-presented-data-supporting-potential-of-szn-1326-at-the-2021-united-european-gastroenterology-week/ 2021-10-05T20:30:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-the-stifel-2021-virtual-healthcare-conference/ 2021-11-05T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-presents-data-supporting-potential-of-szn-043-at-the-liver-meeting-2021the-annual-meeting-of-the-american-association-for-the-study-of-liver-diseases/ 2021-11-15T13:00:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-the-piper-sandler-33rd-annual-healthcare-conference/ 2021-11-15T13:00:00+00:00 https://surrozen.com/press_releases/surrozen-reports-third-quarter-2021-financial-results/ 2021-11-15T21:00:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-virtually-at-the-40th-annual-j-p-morgan-healthcare-conference/ 2022-01-05T13:00:00+00:00 https://surrozen.com/press_releases/surrozen-announces-key-2022-milestones-for-lead-programs-and-acceleration-of-research-pipeline/ 2022-01-10T13:00:00+00:00 https://surrozen.com/press_releases/surrozen-reports-fourth-quarter-and-full-year-2021-financial-results/ 2022-03-24T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-presents-data-supporting-potential-of-szn-413-for-the-treatment-of-diabetic-retinopathy-at-the-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/ 2022-05-02T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-the-bofa-securities-2022-healthcare-conference/ 2022-05-05T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-reports-first-quarter-2022-financial-results/ 2022-05-11T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-publishes-article-in-cellular-and-molecular-gastroenterology-and-hepatology-demonstrating-that-szn-1326-a-selective-wnt-mimeticstimulated-robust-colon-epithelial-regeneration-and-ameliorate/ 2022-05-16T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-initiates-dosing-in-phase-1-clinical-trial-of-szn-1326-for-moderate-to-severe-ulcerative-colitis/ 2022-05-18T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-presents-data-on-lead-therapeutic-candidates-at-digestive-disease-week-ddw/ 2022-05-24T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-initiates-dosing-in-phase-1-clinical-trial-of-szn-043-for-severe-alcoholic-hepatitis/ 2022-06-13T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-reports-second-quarter-2022-financial-results/ 2022-08-11T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-publishes-study-in-translational-vision-science-and-technology-demonstrating-the-promise-of-szn-413-in-preclinical-models-of-diabetic-retinopathy/ 2022-09-26T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-announces-strategic-partnership-with-boehringer-ingelheim-to-develop-wnt-agonist-szn-413-for-people-with-retinal-diseases/ 2022-10-06T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-presents-data-on-two-lead-therapeutic-candidates-at-united-european-gastroenterology-ueg-week/ 2022-10-10T12:00:00+00:00 https://surrozen.com/press_releases/surrozen-reports-third-quarter-2022-financial-results-and-provides-corporate-update/ 2022-11-14T21:30:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference/ 2023-01-04T21:41:00+00:00 https://surrozen.com/press_releases/surrozen-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-a-corporate-update-on-march-222023/ 2023-03-20T20:30:00+00:00 https://surrozen.com/press_releases/surrozen-provides-fourth-quarter-and-full-year-2022-financial-results-and-update-on-clinical-pipeline-and-corporate-progress/ 2023-03-22T20:01:00+00:00 https://surrozen.com/press_releases/surrozen-strengthens-board-of-directors-with-the-appointment-of-eric-bjerkholt/ 2023-04-05T12:30:00+00:00 https://surrozen.com/press_releases/surrozen-provides-first-quarter-2023-financial-results-and-corporate-and-pipeline-updates/ 2023-05-10T20:05:00+00:00 https://surrozen.com/press_releases/surrozen-publishes-study-in-nature-communications-demonstrating-the-promise-of-a-fzd4-wnt-antibody-in-treating-ischemic-stroke/ 2023-06-05T12:30:00+00:00 https://surrozen.com/press_releases/surrozen-provides-second-quarter-2023-financial-results/ 2023-08-09T20:05:00+00:00 https://surrozen.com/press_releases/surrozen-provides-third-quarter-2023-financial-results/ 2023-11-08T21:05:00+00:00 https://surrozen.com/press_releases/surrozen-provides-corporate-update-on-clinical-programs/ 2024-01-18T13:30:00+00:00 https://surrozen.com/press_releases/surrozen-announces-safetypharmacodynamic-and-liver-function-data-for-szn-043/ 2024-04-01T12:30:00+00:00 https://surrozen.com/press_releases/surrozen-announces-up-to-192-5-million-private-placement-of-securities-priced-at-the-market-under-nasdaq-rules/ 2024-04-01T12:30:00+00:00 https://surrozen.com/press_releases/surrozen-publishes-study-in-respiratory-research-demonstrating-the-promise-of-a-wnt-mimetic-antibody-in-treating-pulmonary-fibrosis/ 2024-04-03T12:40:00+00:00 https://surrozen.com/press_releases/surrozen-provides-first-quarter-2024-financial-results-and-business-update/ 2024-05-08T20:05:00+00:00 https://surrozen.com/press_releases/surrozen-presents-data-demonstrating-the-promise-of-antibody-based-wnt-mimetics-in-treating-cornea-endothelial-dystrophies-and-dry-eye-disease-at-the-associations-for-research-in-vision-and-ophthalmol/ 2024-05-09T12:30:00+00:00 https://surrozen.com/press_releases/surrozen-initiates-dosing-of-first-patient-in-phase-1b-clinical-trial-of-szn-043-for-severe-alcohol-associated-hepatitis/ 2024-06-04T12:30:00+00:00 https://surrozen.com/press_releases/surrozen-presents-preliminary-results-from-phase-1a-study-of-szn-043-in-healthy-volunteers-and-patients-with-a-history-of-liver-cirrhosis-at-the-2024-european-association-for-the-study-of-the-liver-e/ 2024-06-10T12:30:00+00:00 https://surrozen.com/press_releases/surrozen-publishes-study-in-elife-demonstrating-the-promise-of-the-proprietary-sweets-platform-a-unique-targeted-protein-degradation-technologyto-further-enhance-wnt-signaling/ 2024-06-12T12:30:00+00:00 https://surrozen.com/press_releases/surrozen-provides-second-quarter-2024-financial-results-and-business-update/ 2024-08-12T20:05:00+00:00 https://surrozen.com/press_releases/surrozen-earns-10-million-milestone-payment-in-retinal-diseases-collaboration/ 2024-09-24T12:30:00+00:00 https://surrozen.com/press_releases/surrozen-and-tcgfbinc-announce-strategic-research-collaboration-to-develop-tgf-β-antibodies-for-idiopathic-pulmonary-fibrosis/ 2024-11-04T13:30:00+00:00 https://surrozen.com/press_releases/surrozen-provides-third-quarter-2024-financial-results-and-business-update/ 2024-11-06T14:00:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-upcoming-healthcare-investor-conferences/ 2024-11-06T21:30:00+00:00 https://surrozen.com/press_releases/surrozen-announces-an-oversubscribed-175-million-private-placement-of-securities-to-focus-on-selective-wnt-mimetic-therapeutics-to-treat-serious-eye-diseases/ 2025-03-24T13:00:00+00:00 https://surrozen.com/press_releases/surrozen-provides-fourth-quarter-and-full-year-2024-financial-results-and-business-updates/ 2025-03-31T20:05:00+00:00 https://surrozen.com/press_releases/surrozen-reports-first-quarter-2025-financial-results-and-provides-business-update/ 2025-05-09T20:05:00+00:00 https://surrozen.com/press_releases/surrozen-granted-patent-from-u-s-patent-and-trademark-office-directed-to-antibody-based-molecules-targeting-key-receptors-in-the-wnt-pathway/ 2025-05-14T12:30:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-upcoming-healthcare-investor-conference-4/ 2025-08-06T20:30:00+00:00 https://surrozen.com/press_releases/surrozen-reports-second-quarter-2025-financial-results-and-provides-business-update/ 2025-08-08T20:05:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-upcoming-healthcare-investor-conference-3/ 2025-08-28T20:15:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-upcoming-healthcare-investor-conference-2/ 2025-09-03T20:15:00+00:00 https://surrozen.com/press_releases/surrozen-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2025-09-04T20:15:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-upcoming-healthcare-investor-conference/ 2025-11-05T21:05:00+00:00 https://surrozen.com/press_releases/surrozen-reports-third-quarter-2025-financial-results-and-provides-business-update/ 2025-11-07T21:05:00+00:00 https://surrozen.com/press_releases/surrozen-reports-inducement-grant-under-nasdaq-listing-rule-5635c4/ 2025-11-12T22:01:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-upcoming-healthcare-investor-conferences-2/ 2025-11-25T21:05:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-upcoming-healthcare-investor-conference-5/ 2026-02-05T04:05:00+00:00 https://surrozen.com/press_releases/surrozen-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2/ 2026-02-23T04:30:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-upcoming-healthcare-investor-conference-6/ 2026-02-25T04:05:00+00:00 https://surrozen.com/press_releases/surrozen-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update/ 2026-03-23T04:05:00+00:00 https://surrozen.com/press_releases/surrozen-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-3/ 2026-04-28T04:05:00+00:00 https://surrozen.com/press_releases/surrozen-reports-first-quarter-2026-financial-results-and-provides-business-update/ 2026-05-06T04:05:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-upcoming-healthcare-investor-conference-7/ 2026-05-12T04:05:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-upcoming-healthcare-investor-conference-8/ 2026-07-15T04:05:00+00:00 https://surrozen.com/press_releases/surrozen-reports-second-quarter-2026-financial-results-and-provides-business-update/ 2026-08-06T04:05:00+00:00 https://surrozen.com/press_releases/surrozen-to-present-at-upcoming-healthcare-investor-conferences-3/ 2026-09-02T04:05:00+00:00 https://surrozen.com/press_releases/surrozen-announces-submission-of-ind-application-for-szn-8141-for-the-treatment-of-diabetic-macular-edema/ 2026-09-08T08:30:00+00:00 https://surrozen.com/press_releases/surrozen-announces-fda-clearance-of-ind-application-for-szn-8141-for-the-treatment-of-diabetic-macular-edema/ 2026-10-02T08:00:00+00:00 https://surrozen.com/press_releases/surrozen-announces-closing-of-second-tranche-of-march-2025-private-placement-for-95-1-million/ 2026-10-20T04:59:00+00:00